No human trial has established a health benefit for ipamorelin. What the research shows is that it releases growth hormone, and does so selectively. In the 1998 Novo Nordisk work, ipamorelin released GH from rat pituitary cells, in rats and in conscious swine. In swine it did not raise ACTH or cortisol beyond the levels seen with GHRH, even at doses more than 200 times the amount needed for GH release (PMID 9849822).
The other study in this page’s record is in rats after abdominal surgery. A single intravenous dose shortened the time to the first bowel movement, and repeated dosing raised food intake and body weight gain (PMID 19289567). That is an animal model, and the human program built on it did not reach approval.
The benefits repeated online, such as body composition, sleep and recovery, come from GH physiology. A 2018 review of the whole secretagogue class says these compounds might improve lean mass, fat-free mass and sleep, and that few long-term, rigorously controlled studies exist (PMID 28400207). Those findings describe the class, not ipamorelin alone.